HC Wainwright & Co. Reiterates Buy on PDS Biotechnology, Maintains $21 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a 'Buy' rating on PDS Biotechnology (NASDAQ:PDSB) and maintained a price target of $21.
October 11, 2023 | 4:37 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
PDS Biotechnology's stock may see positive movement as HC Wainwright & Co. maintains a 'Buy' rating and a price target of $21.
Analyst ratings and price targets can significantly influence investor sentiment and stock price. The reiteration of a 'Buy' rating and a maintained price target of $21 by HC Wainwright & Co. suggests a positive outlook for PDS Biotechnology, which could lead to an increase in its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100